Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19

Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as a pandemic throughout 2020. Since the virus uses angiotensin-converting enzyme 2 (ACE2) as a receptor for cellular entry, increment of ACE2 would lead to an inc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoichiro Takahashi, Akira Hayakawa, Rie Sano, Haruki Fukuda, Megumi Harada, Rieko Kubo, Takafumi Okawa, Yoshihiko Kominato
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e60d2948c75c4ff4b2fa9174ebcc9f91
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e60d2948c75c4ff4b2fa9174ebcc9f91
record_format	dspace
spelling	oai:doaj.org-article:e60d2948c75c4ff4b2fa9174ebcc9f912021-12-02T14:11:31ZHistone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-1910.1038/s41598-021-82970-22045-2322https://doaj.org/article/e60d2948c75c4ff4b2fa9174ebcc9f912021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82970-2https://doaj.org/toc/2045-2322Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as a pandemic throughout 2020. Since the virus uses angiotensin-converting enzyme 2 (ACE2) as a receptor for cellular entry, increment of ACE2 would lead to an increased risk of SARS-CoV-2 infection. At the same time, an association of the ABO blood group system with COVID-19 has also been highlighted: there is increasing evidence to suggest that non-O individuals are at higher risk of severe COVID-19 than O individuals. These findings imply that simultaneous suppression of ACE2 and ABO would be a promising approach for prevention or treatment of COVID-19. Notably, we have previously clarified that histone deacetylase inhibitors (HDACIs) are able to suppress ABO expression in vitro. Against this background, we further evaluated the effect of HDACIs on cultured epithelial cell lines, and found that HDACIs suppress both ACE2 and ABO expression simultaneously. Furthermore, the amount of ACE2 protein was shown to be decreased by one of the clinically-used HDACIs, panobinostat, which has been reported to reduce B-antigens on cell surfaces. On the basis of these findings, we conclude that panobinostat could have the potential to serve as a preventive drug against COVID-19.Yoichiro TakahashiAkira HayakawaRie SanoHaruki FukudaMegumi HaradaRieko KuboTakafumi OkawaYoshihiko KominatoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yoichiro Takahashi Akira Hayakawa Rie Sano Haruki Fukuda Megumi Harada Rieko Kubo Takafumi Okawa Yoshihiko Kominato Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
description	Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as a pandemic throughout 2020. Since the virus uses angiotensin-converting enzyme 2 (ACE2) as a receptor for cellular entry, increment of ACE2 would lead to an increased risk of SARS-CoV-2 infection. At the same time, an association of the ABO blood group system with COVID-19 has also been highlighted: there is increasing evidence to suggest that non-O individuals are at higher risk of severe COVID-19 than O individuals. These findings imply that simultaneous suppression of ACE2 and ABO would be a promising approach for prevention or treatment of COVID-19. Notably, we have previously clarified that histone deacetylase inhibitors (HDACIs) are able to suppress ABO expression in vitro. Against this background, we further evaluated the effect of HDACIs on cultured epithelial cell lines, and found that HDACIs suppress both ACE2 and ABO expression simultaneously. Furthermore, the amount of ACE2 protein was shown to be decreased by one of the clinically-used HDACIs, panobinostat, which has been reported to reduce B-antigens on cell surfaces. On the basis of these findings, we conclude that panobinostat could have the potential to serve as a preventive drug against COVID-19.
format	article
author	Yoichiro Takahashi Akira Hayakawa Rie Sano Haruki Fukuda Megumi Harada Rieko Kubo Takafumi Okawa Yoshihiko Kominato
author_facet	Yoichiro Takahashi Akira Hayakawa Rie Sano Haruki Fukuda Megumi Harada Rieko Kubo Takafumi Okawa Yoshihiko Kominato
author_sort	Yoichiro Takahashi
title	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
title_short	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
title_full	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
title_fullStr	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
title_full_unstemmed	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
title_sort	histone deacetylase inhibitors suppress ace2 and abo simultaneously, suggesting a preventive potential against covid-19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e60d2948c75c4ff4b2fa9174ebcc9f91
work_keys_str_mv	AT yoichirotakahashi histonedeacetylaseinhibitorssuppressace2andabosimultaneouslysuggestingapreventivepotentialagainstcovid19 AT akirahayakawa histonedeacetylaseinhibitorssuppressace2andabosimultaneouslysuggestingapreventivepotentialagainstcovid19 AT riesano histonedeacetylaseinhibitorssuppressace2andabosimultaneouslysuggestingapreventivepotentialagainstcovid19 AT harukifukuda histonedeacetylaseinhibitorssuppressace2andabosimultaneouslysuggestingapreventivepotentialagainstcovid19 AT megumiharada histonedeacetylaseinhibitorssuppressace2andabosimultaneouslysuggestingapreventivepotentialagainstcovid19 AT riekokubo histonedeacetylaseinhibitorssuppressace2andabosimultaneouslysuggestingapreventivepotentialagainstcovid19 AT takafumiokawa histonedeacetylaseinhibitorssuppressace2andabosimultaneouslysuggestingapreventivepotentialagainstcovid19 AT yoshihikokominato histonedeacetylaseinhibitorssuppressace2andabosimultaneouslysuggestingapreventivepotentialagainstcovid19
_version_	1718391877267357696

Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19

Ejemplares similares